Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 18/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | TYK2 | P29597 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15803490 | 0.79 | JAK2 (0.40) | JAK2KCNH2TYK2 | |
| SCHEMBL15760953 | 0.75 | PDPK1 (0.39) | KDM4EALDH1A1HPGD | |
| SCHEMBL15760939 | 0.75 | ZAP70 (0.40) | JAK2KCNH2 | |
| SCHEMBL15803489 | 0.72 | JAK2 (0.41) | JAK2KCNH2TYK2 | |
| SCHEMBL11327610 | 0.66 | JAK2 (0.52) | JAK2 | |
| SCHEMBL15760947 | 0.66 | PARP1 (0.38) | JAK2KCNH2 | |
| SCHEMBL2349754 | 0.63 | — | — | |
| SCHEMBL2460195 | 0.63 | CHEK1 (0.51) | JAK2KCNH2 | |
| SCHEMBL4747249 | 0.62 | JAK2 (0.43) | JAK2KDM4EALDH1A1 | |
| SCHEMBL21987955 | 0.62 | JAK2 (0.39) | JAK2KCNH2KDM4EALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140171429-A1 | BICYCLIC INHIBITORS OF ALK | ABBVIE INC. (US) | 2014-06-19 | — | — | US | disclosed |
| US-20140155389-A1 | BICYCLIC INHIBITORS OF ALK | ABBVIE INC. (US) | 2014-06-05 | — | — | US | disclosed |
| US-20130156721-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTICS DELIVERY | CERULEAN PHARMA INC. (US) | 2013-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140171429-A1 | BICYCLIC INHIBITORS OF ALK | ALK, ACVR1, ACVR1B | JAK2 104/4885KCNH2 485/4885KDM4E 778/4885 |
| US-20140155389-A1 | BICYCLIC INHIBITORS OF ALK | ALK, ABL1, BOD1L1 | JAK2 95/4885KCNH2 573/4885KDM4E 838/4885 |
| US-20130156721-A1 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTICS DELIVERY | DDOST, DSC1, SI | JAK2 2339/4885KCNH2 4447/4885KDM4E 3582/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.